1. Digiuni M, Fogagnolo P, Rossetti L. A review of the use of latanoprost for glaucoma since its launch. Expert Opinion on Pharmacotherapy, 2012. 13(5), 723–745. doi:10.1517/14656566.2012.662219
2. Matsou A, Anastasopoulos E. Investigational drugs targeting prostaglandin receptors for the treatment of glaucoma. Expert Opinion on Investigational Drugs, 2018. 1–9. doi:10.1080/13543784.2018.1526279.
3. National Center for Biotechnology Information. PubChem Compound Summary for CID 5311221, Latanoprost. https://pubchem.ncbi.nlm.nih.gov/compound/Latanoprost. 2021.
9. Wenqiang Z, Qian Y, Zhijian H. Multicenter study on intraocular pressure-lowering efficacy and safety of domestic latanoprost on primary open angle glaucoma and ocular hypertension. China J. Exp. Ophthalmol. 2014;32(12):1107–1110
12. Wenqing G. Efficacy of latanoprost in patients with primary open-angle glaucoma [J] J. Guiyang Med. Coll. 2015;40(7):760–762.
14. Konstas AG, Voudouragkaki IC, Boboridis KG. 24-hour efficacy of travoprost/timolol BAK-free versus latanoprost/timolol fixed combinations in patients insufficiently controlled with latanoprost. Adv. Therapy. 2014;31(6):592–603
15. Blondeau P, Hamid M, Ghalie Z. Prospective randomized clinical trial on the effects of latanoprost, travoprost and bimatoprost on latanoprost non-responders. Journal Français d’Ophtalmologie, 2019. vol. 42, no. 8, pp. 894–899.